Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Decera Clinical Education Oncology Podcast

The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer

30 Jul 2021

Description

In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:Updated safety and patient preference data from the ARAMIS and ODENZA trialsChoice of apalutamide, darolutamide, and enzalutamideCounseling patients on adverse eventsManaging patients with asymptomatic nonmetastatic CRPCPresenters:Karim Fizazi, MD, PhDFull ProfessorCancer MedicineGustave RoussyVillejuif, France  Alicia K. Morgans, MD, MPHAssociate ProfessorDivision of OncologyDepartment of MedicineNorthwestern UniversityChicago, Illinois  Link to full program, including downloadable slides:https://bit.ly/36IEnNE

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.